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To the Editor:
Despite new drug development and improved under-
standing of molecular pathways leading to acute myeloid
leukemia (AML), the cure rate of the disease is still poor.
For high-risk patients or in relapse, the only long-term
curative therapy is still allogeneic hematopoietic stem cell
transplantation (allo-HSCT), which is not feasible in a
considerable number of patients and poses significant risks
in morbidity and mortality. New strategies are urgently
needed to improve the cure rate in AML.
The success of chimeric antigen receptor (CAR)-mod-
ified T-cells directed to the CD19 antigen for the treatment
of lymphoid malignancies of B-cell lineage boosted the
research on CAR T-cells targeting myeloid antigens, such
as CD33, CD123, and Fsm-like tyrosine kinase 3 (FLT3) [1,
2]. FLT3, a tyrosine kinase receptor thought to be specific to
hematopoietic lineage, is an attractive target especially due
to overexpression in AML blasts. In the past few years,
several independent groups developed CAR T-cells target-
ing FLT3 with promising in vitro results [3–5]. The
expression of FLT3 in HSCs might indeed cause concern
[5]. Recent publications have shown CD34+-HSC are less
susceptible to CAR T-cell treatment compared to AML cells
[3, 4]. This is likely due to different affinities of the anti-
bodies used for CAR generation, suggesting different CARs
might have different toxicities in vivo.
T-cell receptor (TCR)-modified T-cell therapy is an
alternative form of adoptive T-cell therapy. Unlike CARs,
which recognize cell surface antigens, TCRs recognize
peptides derived from any cellular proteins presented by
major histocompatibility complex (MHC) molecules.
Therefore, TCRs should not be affected by down modula-
tion of surface antigen expression when intracellular
expression is retained, which is an escape mechanism in
CAR therapies. We have generated an HLA-A2-restricted,
FLT3-specific TCR to target AML cells with the aim of
using it in the context of HLA-A2-mismatched allo-HSCT.
In the proposed set-up, FLT3-directed CD8+ T-cells would
kill any remaining HLA-A2+/FLT3+ cells possibly eradi-
cating all leukemic cells while allowing the engraftment and
establishment of an HLA-A2-, leukemia free hematopoiesis.
It is not possible to generate optimal-affinity TCRs
against self-antigens in humans because of thymic selection.
To circumvent tolerance and develop optimal-affinity TCR
against FLT3, we immunized mice expressing a diverse
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human TCR repertoire and a mouse CD8-binding HLA-A2
molecule (ABabDII) with an in silico-predicted FLT3 epi-
tope [6]. The FLT3982-991 peptide GLLSPQAQV (GLL),
with an affinity of 56 nM to HLA-A2 predicted by NetMHC
3.4, was selected for immunizations (Fig. 1a). ABabDII
mice were immunized and boosted with GLL peptide and
peripheral blood was analyzed for peptide-specific T-cells
7 days after immunization. Reactive CD8+ T-cells were
collected from inguinal lymph nodes and spleen of two
mice (#6780 and #6782) and expanded with peptide in vitro
for 10 days. By an IFN-γ capture assay, 2,500 and 65,300
IFN-γ+-CD8+ T-cells were sorted, respectively (Supp.
Figure 1). TCRs were isolated by RACE-PCR and Vα and
Vβ pairs were identified based on their abundance (Supp.
Table 1). We constructed codon-optimized TCR cassettes
with mouse constant region for better expression in human
T-cells (named TCR-6780 and TCR-6782) in the
γ-retroviral vector pMP71 as described [7].
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Fig. 1 Characterization of FLT3-specific TCRs generated from
ABabDII mice. a) Alignment of human and mouse FLT3 protein
spanning the FLT3982-991 T-cell epitope GLLSPQAQV used for
immunization. Full proteins are 83% identical to each other with N-
terminal regions sharing minimum homology. b) Flow cytometry
analysis of human PBMCs transduced with TCR-6780 and TCR-6782.
The cells were stained with antibodies against human CD8, mTRBC,
and FLT3982-991-HLA-A2 tetramer three days after the transduction.
TCR-transduced CD8+ T-cells bind to the FLT3982-991-HLA-A2 tet-
ramer showing correct pairing of TCR α and β variable chains. The
transduction rate varied between 20 and 60% in different experiments
depending on the retrovirus titer. c) IFN-γ release by TCR-transduced
T-cells upon co-culture with T2 cells loaded with increasing con-
centration of GLL peptide. d) Recognition of K562 cells over-
expressing HLA-A2 and FLT3 showing natural processing and
presentation of FLT3982-991 epitope. e) CD137 upregulation on the
surface of the TCR-transduced CD8+ T-cells upon co-culture with cell
lines expressing FLT3. THP1 cells (FLT3+/HLA-A2+) were recog-
nized only by TCR-6780 when FLT3 was overexpressed. SEM and
MV-4;11 cell lines (FLT3+/HLA-A2-) induced CD137 on TCR-6780-
transduced T-cells when HLA-A2 was introduced by transduction.
FACS plots and graphs represent results from one out of three donors
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Following retroviral transduction, GLL-specific TCRs
were expressed in human CD8+ T-cells, as confirmed by
staining against the mouse constant TCRβ region (mTRBC)
and FLT3982-991-HLA-A2 tetramers (Fig. 1b). Transduced
T-cells were co-cultured with T2 cells loaded with
decreasing concentration of GLL peptide at 1:1 ratio over-
night, IFN-γ was detected in the supernatant by ELISA.
Both TCR-6780 and TCR-6782 recognized GLL peptide at
a concentration as low as 10 nM (Fig. 1c). Half-maximum
IFN-γ release at 17 and 100 nM peptide concentrations,
respectively, indicates TCR-6780 has a higher functional
avidity, although the affinity still appears to be suboptimal.
We generated K562 cell lines expressing HLA-A2,
FLT3, or both by γ-retroviral transduction for co-cultivation
assays (Supp. Figure 2). TCR-transduced T-cells recognized
K562/HLA-A2 cells loaded with the GLL peptide (Fig. 1d).
TCR-6780-transduced T-cells secreted IFN-γ to K562 cells
co-expressing HLA-A2 and FLT3, proving the epitope was
naturally processed and presented while TCR-6782-
transduced T-cells did not secrete IFN-γ, indicating a
lower functional TCR avidity (Fig. 1d). Next, TCR-6780
and TCR-6782 transduced T-cells were co-cultured with
cells expressing FLT3 endogenously (THP1 is derived from
AML patient; MV;4-11 is a mixed-lineage myelomonocytic
leukemia line carrying the 4;11 chromosomal translocation;
SEM is a B-cell precursor leukemia cell line). SEM and
MV;4-11 cells were retrovirally transduced to stably
express HLA-A2. The target cells were labeled with 1 µM
CFSE prior to overnight co-culture with TCR-transduced
CD8+ T-cells and CD137 upregulation specifically on
TCR-transduced CD8+ T-cells was analyzed (Supp. Fig 3
for gating strategy). TCR-6780-transduced T-cells recog-
nized cell lines co-expressing FLT3 and HLA-A2 to a dif-
ferent extent. 1.8% of TCR-6780-transduced CD8+ T-cells
upregulated CD137 in response to THP1 cells in contrast to
25.33% in response to THP-1 overexpressing FLT3. SEM
and MV;4-11 were recognized when they expressed HLA-
A2 only (14.9% and 14.3%, respectively). TCR-6782-
transduced CD8+ T-cells did not upregulate CD137, likely
because of low avidity (Fig. 1e). We could not detect IFN-γ
from effector cells upon co-culture with target cells indi-
cating low avidity of both TCRs (data not shown).
Several FLT3 inhibitors are being used for the treatment
of AMLs without life-threatening side effects or toxicity [8].
Anti-FLT3 monoclonal antibodies have entered a clinical
trial in AML. TCR-engineered T-cells are more potent in
terms of killing target cells. Theoretically, a single molecule
of the antigen presented on the MHC can elicit T-cell
toxicity [9]. Hence, TCR-mediated on-target recognition of
vital tissues may induce severe toxicity [10–12]. So far,
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Fig. 2 Expression profiling of FLT3 in normal human brain. a) FLT3
was amplified from commercially available nerve tissue cDNA array
representing 24 different anatomical sites of the normal human brain.
High expression was detected in the cerebellum. b) RT-PCR (left) and
western blot analysis (right) detected FLT3 expression in human cer-
ebellar samples. FLT3 amplicon was detected from cDNA of fresh
cerebellar samples from three different healthy donors. For western
blot analysis, 100 µg total cerebellar protein extract and 40 µg total
protein from the THP1 cell line were separated on SDS-PAGE gel for
immunoblotting. While the 160 kDa band corresponding to plasma
membrane associated, glycosylated FLT3 was not detected, the 135
kDa band of underglycosylated FLT3 associated with endoplasmic
reticulum membrane was detected using total cerebellar protein
extract. Protein lysate of the frontal lobe was used as negative control
and THP1 cell line served as positive control. c) Immunohistochemical
analysis of the cerebellum with granular layer (GL), Purkinje cell
layer, and molecular layer (ML). The molecular layer contains the
dendritic arbors, the Purkinje cell layer the cell bodies of Purkinje
neurons (PC) that strongly express calbindin (A, arrows; B, arrow).
Double immunohistochemical staining of PCs reveal strong cyto-
plasmic expression of calbindin (C, D), membranous expression of
CD56 (NCAM; C-F) and cytoplasmic expression of FLT3 (E, F,
arrow). Confocal microscopy with double immunofluorescence stain-
ing shows a maximum projection of a stack of images (G, H) and a
single plane of one stack of images at a higher magnification (I–L).
CD56 (NCAM, green) is localized on the cell membrane (I, arrow-
heads) whereas FLT3 (red) is exclusively found in the cytoplasm of
PCs (J). No co-localization of CD56 and FLT3 was detected on the
cytoplasmic membrane (L, arrowheads)
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there was no evidence in the literature that non-
hematopoietic human cells express FLT3 and Flt3 knock-
out mice develop normally but have an impaired lymphoid
progenitor cell compartment [13], suggesting FLT3 may
indeed be specific to the hematopoietic compartment.
To assess the safety of FLT3 as a target antigen, we used
a cDNA library representing 48 healthy human tissues. We
first verified the sensitivity of the PCR reaction on a titration
of FLT3+ THP1 cell line (Supp. Fig 4a). In RT-PCR, a 236
bp FLT3 amplicon was detected in several tissues including
the brain (Supp. Fig 4b). Testing an additional cDNA
library spanning 24 tissues of the central nervous system
(CNS) by RT-PCR revealed that FLT3 was highly expres-
sed in the cerebellar hemispheres and vermis (Fig. 2a).
Detected PCR products were confirmed to be FLT3 by
Sanger sequencing (Supp. Fig 4c), thus, unveiling those
sites as potential sites of on-target off-tumor toxicity.
Next, we analyzed postmortem human brain tissue.
Total protein and total RNA from three different individuals
were isolated from the cerebellar vermis (CV) and cerebellar
hemispheres (CH). FLT3 gene expression was verified by
RT-PCR (Fig. 2b). FLT3 is synthesized and glycosylated in
the endoplasmic reticulum (ER), then transported to the cell
membrane. The membrane-bound, glycosylated FLT3 is
detected as 160 kDa band while ER-bound immature FLT3
is 135 kDa. We detected only 135 kDa immature FLT3 in
the cerebellar lysate by western blot analysis suggesting
FLT3 is found primarily intracellular, most likely bound to
the ER membrane in cerebellum tissue (Fig. 2b). In mice,
Flt3 has been detected in the mouse cerebellum, specifically
in Purkinje cells (PC) [14]. Immunohistochemical (IHC) and
immunofluorescent (IF) staining were used to further eluci-
date which cerebellar cell type expresses FLT3. Immuno-
fluorescent co-staining of CD56 (neural cell adhesion
molecule (NCAM)) and FLT3 revealed a cytoplasmic and
intracellular expression of FLT3 in Purkinje cells, confirm-
ing the western blot results (Fig. 2c).
In conclusion, we generated two TCRs recognizing the
self-epitope FLT3982-991 presented in the context of HLA-
A2. We showed for the first time that the FLT3982-991
epitope is naturally processed and presented and therefore
a potential TCR target. The first TCRs we generated did
not show optimal-affinity, hence, could not be used for
kill assays on AML cell lines as well as on-target toxicity
assessment. However, the unexpected intracellular
expression of FLT3 in Purkinje cells appears to bear a risk
that is too high to move forward with TCR into the clinic
because of the anticipated on-target off-tumor recognition.
Purkinje cells integrate afferent signals mainly from the
brainstem and send their axons down to the deep cere-
bellar nuclei. PC degeneration causes coordination defi-
cits, such as limb ataxia, dysarthria, and oculomotor
disturbances, as seen in paraneoplastic syndromes.
Therefore, we abandoned the effort to generate a TCR
with improved affinity by novel immunizations and the
whole strategy of targeting FLT3 with TCR-transduced T-
cells. Nevertheless, our findings do not necessarily infer
that FLT3 is not a suitable target for CAR therapy. First,
antibody-based therapeutics may not be efficient enough
to kill a cell if the surface expression is weak, while few
pMHC complexes might be enough for recognition and
killing by TCRs [9, 15]. Second and most important,
according to our data, FLT3 is likely to be present intra-
cellularly but not on the surface of human Purkinje cells
and is therefore unlikely to be recognized by a CAR. The
urgent need for novel therapies in AML might well justify
pursuing this strategy in high-risk patients.
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To the Editor:
Isocitrate dehydrogenase (IDH1/2) genes encode for ubi-
quitinously expressed enzymes that catalyze a redox reaction
that converts isocitrate to α-ketoglutarate while reducing
NADP to NADPH and liberating CO2 [1]. IDH1 exerts his
function in the cytoplasm and peroxisomes whilst IDH2 is
localized in the mitochondrial matrix [1]. When mutated, the
IDH1 and IDH2 enzymes acquire a neomorphic activity
leading to the conversion of α-ketoglutarate to D-2-
hydroxyglutarate [2–4]. The latter compound acts as an
oncometabolite by inhibiting the α-ketoglutarate-dependent
enzymes that regulates epigenetic modeling, collagen
synthesis and cell signaling [1]. IDH1 and IDH2 mutations
are mutually exclusive with TET2 mutations that are known
to promote leukemia with a similar mechanism [5].
IDH1 gene mutations have been detected in 6.6–7.6% [6, 7]
of AML patients, most frequently carrying a normal karyotype,
and their presence has not been associated with prognostic
relevance. They are heterozygous missense mutations confined
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